• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets

tetano

Editor, Senior Moderator
Vaccine. 2014 Apr 7. pii: S0264-410X(14)00453-8. doi: 10.1016/j.vaccine.2014.03.072. [Epub ahead of print]
Hemozoin is a potent adjuvant for hemagglutinin split vaccine without pyrogenicity in ferrets.
Onishi M1, Kitano M2, Taniguchi K2, Homma T2, Kobayashi M2, Sato A2, Coban C3, Ishii KJ4.
Author information
Abstract
BACKGROUND:

Synthetic hemozoin (sHZ, also known as β-hematin) from monomeric heme is a particle adjuvant which activates antigen-presenting cells (APCs), such as dendritic cells and macrophages, and enhances humoral immune responses to several antigens, including ovalbumin, human serum albumin, and serine repeat antigen 36 of Plasmodium falciparum. In the present study, we evaluated the adjuvanticity and pyrogenicity of sHZ as an adjuvant for seasonal trivalent hemagglutinin split vaccine (SV) for humans using the experimental ferret model.
METHOD:

Ferrets were twice immunized with trivalent SV, SV with sHZ (SV/sHZ) or Fluad, composed of trivalent SV with MF59. Serum hemagglutination inhibition (HI) titers against three viral hemagglutinin (HA) antigens were measured at every week after the immunization. The pyrogenicity of SV/sHZ was examined by monitoring the body temperature of the immunized ferrets. To evaluate the protective efficacy of SV/sHZ, the immunized ferrets were challenged with influenza virus B infection, followed by measurement of viral titers in the nasal cavity and body temperature.
RESULTS:

sHZ enhanced HI titers against three viral HA antigens in a dose-dependent manner, to an extent comparable to that of Fluad. The highest dose of sHZ (800μg) immunized with SV conferred sterile protection against infection with heterologous Influenza B virus, without causing any pyrogenic reaction such as high fever.
CONCLUSION:

In the present study, sHZ enhanced the protective efficacy of SV against influenza infection without inducing pyrogenic reaction, suggesting sHZ to be a promising adjuvant candidate for human SV.

Copyright ? 2014 The Authors. Published by Elsevier Ltd.. All rights reserved.
KEYWORDS:

Adjuvant, Ferret, Fluad, Influenza, Seasonal trivalent HA split vaccine, Vaccine

PMID:
24721532
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/24721532
 
Back
Top Bottom